The limited effect of omega-3 polyunsaturated fatty acids on cardiovascular risk in patients with impaired glucose metabolism: a meta-analysis

Clinical Biochemistry
Tengfei ZhengMing Zhong

Abstract

The impacts of marine-derived n-3 polyunsaturated fatty acids (n-3 PUFAs) on cardiovascular risk are not well known. We conducted this meta-analysis to determine the effects of n-3 PUFAs on cardiovascular outcomes and cardiovascular risk markers in patients with impaired glucose metabolism (IGM). We searched PUBMED, EMBASE, The Cochrane Library and reference lists of relevant papers for high quality randomized controlled trials comparing dietary intake of n-3 PUFAs with placebo in IGM patients. Data was extracted and quality assessed independently by two reviewers. Authors were contacted for missing information. Overall estimates were calculated using a random-effects model or a fixed-effects model, and the possibility of publication bias was examined using a funnel plot. Subgroup analyses were conducted to explore the association between the risk markers and study characteristics. Our meta-analysis included 19 studies, 24,788 patients. Compared with placebo, n-3 PUFAs had no statistically significant reduce effect on cardiovascular mortality, major cardiovascular events, all-cause mortality or composite endpoint of all-cause mortality or hospitalization for cardiovascular cause, however it can significantly reduce the level of...Continue Reading

References

Aug 1, 1990·Diabetes Care·T J HendraJ S Yudkin
Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Oct 6, 1997·BMJ : British Medical Journal·M R TramèrH J McQuay
Nov 22, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A P Simopoulos
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Nov 13, 2008·Diabetologia·R R HolmanUNKNOWN Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group
Jun 23, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Sh PooyaF Toorang
Jul 11, 2009·Expert Review of Cardiovascular Therapy·Roberto MarchioliUNKNOWN GISSI-HF Investigators
Jan 15, 2010·The American Journal of Clinical Nutrition·Alin StirbanDiethelm Tschoepe
Oct 12, 2010·The New England Journal of Medicine·Daan KromhoutUNKNOWN Alpha Omega Trial Group
Dec 1, 2010·BMJ : British Medical Journal·Pilar GalanUNKNOWN SU.FOL.OM3 Collaborative Group
Sep 13, 2012·JAMA : the Journal of the American Medical Association·Evangelos C RizosMoses S Elisaf

❮ Previous
Next ❯

Citations

Sep 24, 2015·International Journal of Molecular Sciences·Hanne K MaehreKarl-Erik Eilertsen
Oct 4, 2016·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G ColussiL A Sechi
Jul 19, 2018·The Cochrane Database of Systematic Reviews·Asmaa S AbdelhamidLee Hooper
Dec 7, 2018·The Cochrane Database of Systematic Reviews·Asmaa S AbdelhamidLee Hooper
Oct 24, 2018·Nutrients·Ewa Sokoła-WysoczańskaBożena Patkowska-Sokoła
Mar 3, 2020·The Cochrane Database of Systematic Reviews·Asmaa S AbdelhamidLee Hooper

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.